| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2382 |
| Trial ID | NCT04432506 |
| Disease | Primary Mediastinal B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Diffuse Large B-Cell Lymphoma | B-Cell Lymphoma | Hematopoietic and Lymphoid Cell Neoplasm | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | YesCAR-Ta|Axicabtagene Ciloleucel|axi-cel |
| Co-treatment | Anakinra |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma |
| Year | 2020 |
| Country | United States |
| Company sponsor | M.D. Anderson Cancer Center |
| Other ID(s) | 2019-1051|NCI-2020-04369|2019-1051 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||